REDH database provides insights into RNA editing in hematopoietic cells

In July 2022, we reported on the impending launch of the 988 Suicide & Crisis Lifeline. In this report, we follow up on what has

Take­da an­nounced Mon­day morn­ing that the TYK2 in­hibitor it bought from Nim­bus Ther­a­peu­tics for $4 bil­lion has suc­ceed­ed in a Phase IIb tri­al in pso­ri­at­ic